Martin D. Meglasson
Upjohn
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Martin D. Meglasson.
Journal of Pharmacology and Experimental Therapeutics | 2009
Eric G. Vajda; Francisco J. López; Peter Rix; Rob Hill; Yanling Chen; Kyoung-Jin Lee; Zhihong O'Brien; William Y. Chang; Martin D. Meglasson; Yong-Hee Lee
Selective androgen receptor modulators (SARMs) are a new class of molecules in development to treat a variety of diseases. SARMs maintain the beneficial effects of androgens, including increased muscle mass and bone density, while having reduced activity on unwanted side effects. The mechanisms responsible for the tissue-selective activity of SARMs are not fully understood, and the pharmacokinetic (PK)/pharmacodynamic (PD) relationships are poorly described. Tissue-specific compound distribution potentially could be a mechanism responsible for apparent tissue selectivity. We examined the PK/PD relationship of a novel SARM, LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinolin-7(6H)-one], in a castrated rat model of androgen deficiency. LGD-3303 has potent activity on levator ani muscle but is a partial agonist on the preputial gland and ventral prostate. LGD-3303 never stimulated ventral prostate above intact levels despite increasing plasma concentrations of compound. Tissue-selective activity was maintained when LGD-3303 was dosed orally or by continuous infusion, two routes of administration with markedly different time versus exposure profiles. Despite the greater muscle activity relative to prostate activity, local tissue concentrations of LGD-3303 were higher in the prostate than in the levator ani muscle. LGD-3303 has SARM properties that are independent of its pharmacokinetic profile, suggesting that the principle mechanism for tissue-selective activity is the result of altered molecular interactions at the level of the androgen receptor.
Biochemical Pharmacology | 1991
Ohta Mitsuaki; David Nelson; June Nelson; Martin D. Meglasson; Maria Erecińska
To define better the role of [ATP]/[ADP] in insulin release from pancreatic islets, changes in the adenine nucleotide ratios elicited by alterations in external pH were correlated with the secretion profiles produced by administration of two metabolic secretagogues, 16 mM glucose and 10 mM alpha-ketoisocaproic acid. Experiments were carried out in buffers with and without bicarbonate, in the pH range 6.5-7.7. Insulin release was dependent on pHe irrespective of the secretagogue used. Secretion profiles for alpha-ketoisocaproic acid were the same both with and without bicarbonate; the release was decreased below pH 7.1 but maintained at 7.4-7.7. The same pattern was seen with glucose in media buffered with Hepes. With bicarbonate present, secretion caused by high glucose showed a bell-shaped dependence on [H+], with reductions at the acid and alkaline sides of pH 7.1-7.4. [ATP] and [ADP] were higher when Hepes was the buffer, at all pH values studied. The [ATP]/[ADP] declined with increasing pH under both basal and stimulated conditions; the values were always larger after stimulation although at pH 7.7 with bicarbonate present and glucose as the stimulant the difference was very small. It is concluded that: (i) the [ATP]/[ADP] in pancreatic islets is markedly dependent on pHe; (ii) there is no straight-forward correlation between either [ATP] or the absolute value for [ATP]/[ADP] and insulin secretion; and (iii) a rise in [ATP]/[ADP] is necessary for glucose-stimulated insulin release although it is not always the rate-determining event.
Biochemical Pharmacology | 1992
Mitsuaki Ohta; David Nelson; Jeanne M. Wilson; Martin D. Meglasson; Maria Erecińska
Perifusion of islets with nominally phosphate-free buffer containing increasing concentrations of 2-deoxy-D-glucose (2.5 to 10 mM) produced increments in high alpha-ketoisocaproic acid-induced secretion of insulin beyond those observed in the absence of the sugar analogue. 3-O-methyl-D-glucose, a poorly metabolized sugar, was without effect. Insulin release evoked by 40 mM KCl was not altered by 2-deoxyglucose. The concentration of intracellular inorganic phosphate was lower in islets perifused with 2-deoxyglucose and declined to a lower level after addition of 20 mM alpha-ketoisocaproic acid. The enhancement of alpha-ketoisocaproic acid-induced hormone secretion by 2-deoxyglucose was not seen in islets perifused with medium containing 1.5 mM phosphate; instead a small inhibition was observed. It is postulated that conditions which lower intracellular [Pi] facilitate, either directly or indirectly, hormone release although the mechanism of this effect remains to be elucidated.
Journal of Pharmacology and Experimental Therapeutics | 1993
M Ohta; J Nelson; D Nelson; Martin D. Meglasson; M Erecińska
Journal of Medicinal Chemistry | 2001
Valerie A. Vaillancourt; Scott D. Larsen; Steven P. Tanis; Jeffery E. Burr; Mark A. Connell; Michele M. Cudahy; Bruce R. Evans; Peter V. Fisher; Paul D. May; Martin D. Meglasson; Deborah D. Robinson; F. Craig Stevens; John A. Tucker; and Thomas J. Vidmar; Jen H. Yu
Archive | 1993
Jerry R. Colca; Scott D. Larsen; Martin D. Meglasson; Steven P. Tanis
Journal of Pharmacology and Experimental Therapeutics | 2005
Diane Stephenson; Martin D. Meglasson; Mark A. Connell; Mary A. Childs; Eva Hajos-Korcsok; Marina E. Emborg
Archive | 1995
Scott D. Larsen; Valerie A. Vaillancourt; Paul D. May; Steven P. Tanis; John A. Tucker; Martin D. Meglasson; Heinrich J. Schostarez
Archive | 1991
Martin D. Meglasson
Archive | 1992
Martin D. Meglasson